aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...
KRQE Blogs

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks ...
Medscape

ECG Helps Detect Cardiac Involvement in Sarcoidosis

In a study of patients with cutaneous sarcoidosis, ECG abnormalities identified all cases of cardiac involvement, demonstrating 100% sensitivity and 100% negative predictive value. Researchers ...